Trials / Terminated
TerminatedNCT04847583
A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients
A Phase 2 Open-Label, Randomized Controlled Trial to Evaluate the Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec in Participants With Moderate COVID-19 Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Qurient Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, open-label, randomized controlled trial to determine the effects of Telacebec (Q203) on inhibition of leukotriene production, clinical change, pharmacokinetics, and safety in participants with moderate COVID-19 disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telacebec | Telacebec 100 mg tablet |
| DRUG | COVID-19 Standard of care | The Standard of Care treatment and administration thereof will be determined by the Investigator |
Timeline
- Start date
- 2021-07-29
- Primary completion
- 2022-02-11
- Completion
- 2022-02-11
- First posted
- 2021-04-19
- Last updated
- 2022-03-02
Locations
3 sites across 1 country: South Africa
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04847583. Inclusion in this directory is not an endorsement.